Coxibs and Serious Adverse Cardiovascular Events: A Class-Effect?

Sandler R.S. , Halabi S. , Baron J.A. . A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348: 883–90

Baron J.A. , Cole B.F. , Sandler R.S. . A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348: 891–9

Bombardier C. , Laine L. , Reicin A. . Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520–8

Silverstein F.E. , Faich G. , Goldstein J.L. . Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247–55

Witter J. Medical Officer review [www.fda.gov/ohrms/dockets/ac/01/briefing/3677b103med.pdf]

Hrachovec J.B. , Mora M. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. JAMA 2001; 286: 2398–400

Chan F.K. , Hung L.C. , Suen B.Y. . Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002; 347: 2104–10